A review of emerging factor XI inhibitors

Autor: Sandra Elsheikh, Nicola Tidbury, Gregory Y.H. Lip

Publikováno v: Elsheikh, S, Tidbury, N & Lip, G Y H 2023, ' A review of emerging factor XI inhibitors ', Expert Opinion on Emerging Drugs, vol. 28, no. 1, pp. 43-53 . https://doi.org/10.1080/14728214.2023.2192923

Introduction: Whilst the introduction of direct oral anticoagulants (DOACs) has improved the prevention of thromboembolic events, there is still a need for safer anticoagulants. This is particularly so, for specific populations of patients, such as t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe58841fb103e8b159bdccc17c5c026
https://doi.org/10.1080/14728214.2023.2192923

Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response

Autor: Wern Yew Ding, Nicola Tidbury, Francisco Marín, Joshua Preston, José Miguel Rivera-Caravaca, Gregory Y.H. Lip

Publikováno v: Tidbury, N, Preston, J, Ding, W Y, Rivera-Caravaca, J M, Marín, F & Lip, G Y H 2020, ' Utilizing biomarkers associated with cardiovascular events in atrial fibrillation : informing a precision medicine response ', Expert Review of Precision Medicine and Drug Development, vol. 5, no. 5, pp. 331-345 . https://doi.org/10.1080/23808993.2020.1804864
Expert Review of Precision Medicine and Drug Development

Introduction: Atrial fibrillation is the most common sustained cardiac rhythm disorder, which currently affects 1–2% of the global population. Furthermore, the incidence and prevalence of atrial fibrillation is rising. Biomarkers have the potential

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd84971b91fa01fe2e6bc4b2440f240
https://doi.org/10.1080/23808993.2020.1804864